Picture of AxoGen logo

AXGN — AxoGen News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

AxoGen Inc expected to post a loss of 11 cents a share - Earnings Preview

* AxoGen Inc  AXGN.OQ   AXGN.O  is expected to show a rise
in
quarterly revenue when it reports  results on March 14. 
    * The Alachua Florida-based  company is expected to report 
a
14.8% increase in revenue to $36.2 million from $31.54 million a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data. The company's guidance on January 9 2023, for
the period ended December 31, was for revenue of $36.100
million.
    * ​Refinitiv's mean analyst estimate for AxoGen Inc is for a
loss
of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AxoGen Inc
is
$16​, above​ its last closing price of $7.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.13       -0.12      -0.01     Beat    91.8
 Jun. 30 2022  -0.14       -0.14      -0.06     Beat    58.6
 Mar. 31 2022  -0.16       -0.15      -0.20     Missed  -30.4​
 Dec. 31 2021  -0.12       -0.13      -0.08     Beat    39.1
 ​​Sep.        -0.14       -0.14      -0.09     Beat    34.4
 30 2021                                                
 Jun. 30 2021  -0.13       -0.13      -0.09     Beat    29.9​
 Mar. 31 2021  -0.17       -0.16      -0.08     Beat    49.5
 Dec. 31 2020  -0.11       -0.12      -0.08     Beat    35.6
 This summary was machine generated March 10 at 13:43 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on AxoGen

See all news